858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, HR+/HER2- Unresectable or Metastatic Breast Cancer
— Fast Track designation granted by U.S.
FDA for evaluation of ETX-19477 in patients with BRCA-mutated HR+/HER2- unresectable or metastatic breast cancer — — Enables access to expedited regulatory review processes, inclu
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.
